Clovis Oncology, Inc. (CLVS): Price and Financial Metrics


Clovis Oncology, Inc. (CLVS): $1.71

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CLVS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CLVS POWR Grades


  • Growth is the dimension where CLVS ranks best; there it ranks ahead of 74.38% of US stocks.
  • The strongest trend for CLVS is in Value, which has been heading up over the past 179 days.
  • CLVS ranks lowest in Momentum; there it ranks in the 4th percentile.

CLVS Stock Summary

  • Clovis Oncology Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 4.65% of US listed stocks.
  • CLVS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.78% of US stocks.
  • The volatility of Clovis Oncology Inc's share price is greater than that of 91.61% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Clovis Oncology Inc, a group of peers worth examining would be ARDX, FBIO, TVTX, SMCI, and INSM.
  • Visit CLVS's SEC page to see the company's official filings. To visit the company's web site, go to www.clovisoncology.com.

CLVS Valuation Summary

  • CLVS's price/sales ratio is 3.6; this is 68.28% lower than that of the median Healthcare stock.
  • Over the past 119 months, CLVS's price/sales ratio has gone NA NA.
  • CLVS's EV/EBIT ratio has moved up 1 over the prior 119 months.

Below are key valuation metrics over time for CLVS.

Stock Date P/S P/B P/E EV/EBIT
CLVS 2021-08-31 3.6 -2.8 -1.8 -3.6
CLVS 2021-08-30 3.6 -2.8 -1.8 -3.6
CLVS 2021-08-27 3.5 -2.7 -1.8 -3.6
CLVS 2021-08-26 3.4 -2.6 -1.7 -3.5
CLVS 2021-08-25 3.5 -2.6 -1.8 -3.5
CLVS 2021-08-24 3.5 -2.6 -1.7 -3.5

CLVS Growth Metrics

    The year over year revenue growth rate now stands at 4.96%.
  • The 3 year net cashflow from operations growth rate now stands at -26.15%.
  • Its 4 year price growth rate is now at -41.27%.
Over the past 15 months, CLVS's revenue has gone down $11,773,000.

The table below shows CLVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 148.757 -196.057 -264.524
2021-09-30 156.088 -210.767 -299.093
2021-06-30 156.944 -219.022 -310.359
2021-03-31 160.011 -232.124 -336.158
2020-12-31 164.522 -252.728 -369.212
2020-09-30 160.53 -266.822 -369.756

CLVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CLVS has a Quality Grade of C, ranking ahead of 53.47% of graded US stocks.
  • CLVS's asset turnover comes in at 0.279 -- ranking 164th of 682 Pharmaceutical Products stocks.
  • NEOG, FLXN, and NSTG are the stocks whose asset turnover ratios are most correlated with CLVS.

The table below shows CLVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.279 0.744 -0.373
2021-06-30 0.271 0.746 -0.388
2021-03-31 0.269 0.746 -0.423
2020-12-31 0.271 0.749 -0.454
2020-09-30 0.258 0.753 -0.415
2020-06-30 0.244 0.754 -0.408

CLVS Price Target

For more insight on analysts targets of CLVS, see our CLVS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 2.17 (Hold)

CLVS Stock Price Chart Interactive Chart >

Price chart for CLVS

CLVS Price/Volume Stats

Current price $1.71 52-week high $5.92
Prev. close $1.71 52-week low $0.58
Day low $1.55 Volume 4,219,000
Day high $1.71 Avg. volume 10,658,338
50-day MA $1.24 Dividend yield N/A
200-day MA $2.54 Market Cap 246.03M

Clovis Oncology, Inc. (CLVS) Company Bio


Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The company was founded in 2009 and is based in Boulder, Colorado.


CLVS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLVS Latest Social Stream


Loading social stream, please wait...

View Full CLVS Social Stream

Latest CLVS News From Around the Web

Below are the latest news stories about Clovis Oncology Inc that investors may wish to consider to help them evaluate CLVS as an investment opportunity.

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

BOULDER, Colo., February 25, 2022--LuMIERE TiP at SNMMI mid-Winter and ACNM meeting curtain raiser news release

Yahoo | February 25, 2022

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Yahoo | February 24, 2022

Clovis Oncology GAAP EPS of -$0.50, revenue of $35.97M

Clovis Oncology press release (NASDAQ:CLVS): Q4 GAAP EPS of -$0.50. Revenue of $35.97M (-16.9% Y/Y). “We have been looking forward to 2022 for a long time, which we anticipate will be the most significant year for clinical data read-outs in the Company’s history,” said Patrick J. Mahaffy, President and CEO of...

Seeking Alpha | February 23, 2022

Clovis Oncology, Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by Clovis Oncology, Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 23, 2022

Recap: Clovis Oncology Q4 Earnings

Clovis Oncology (NASDAQ: CLVS ) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Clovis Oncology beat estimated earnings by 14.29%, reporting an EPS of $-0.48 versus Full story available on Benzinga.com

Benzinga | February 23, 2022

Read More 'CLVS' Stories Here

CLVS Price Returns

1-mo 145.94%
3-mo -31.60%
6-mo -36.90%
1-year -70.52%
3-year -88.86%
5-year -98.17%
YTD -36.90%
2021 -43.54%
2020 -53.96%
2019 -41.95%
2018 -73.59%
2017 53.08%

Continue Researching CLVS

Here are a few links from around the web to help you further your research on Clovis Oncology Inc's stock as an investment opportunity:

Clovis Oncology Inc (CLVS) Stock Price | Nasdaq
Clovis Oncology Inc (CLVS) Stock Quote, History and News - Yahoo Finance
Clovis Oncology Inc (CLVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4629 seconds.